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Abstract: A voluminous literature suggests that an increase in consumption of fruit and 
vegetables is a relatively easy and practical strategy to reduce significantly the incidence of 
cancer. The beneficial effect is mostly associated with the presence of phytochemicals in 
the diet. This review focuses on a group of them, namely isothiocyanate, curcumin, 
genistein, epigallocatechin gallate, lycopene and resveratrol, largely studied as 
chemopreventive agents and with potential clinical applications. Cellular and animal 
studies suggest that these molecules induce apoptosis and arrest cell growth by pleiotropic 
mechanisms. The anticancer efficacy of these compounds may result from their use in 
monotherapy or in association with chemotherapeutic drugs. This latter approach may 
represent a new pharmacological strategy against several types of cancers. However, 
despite the promising results from experimental studies, only a limited number of clinical 
trials are ongoing to assess the therapeutic efficacy of these molecules. Nevertheless, the 
preliminary results are promising and raise solid foundations for future investigations. 
Keywords:  isothiocyanate; curcumin; genistein; epigallocatechin gallate; lycopene; 
resveratrol; glucosinolates; clinical trials; apoptosis; phytochemicals 
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1. Introduction 
To date, several hundred scientific studies focused on the activity of non-nutritional compounds 
present in the diet, preventing the occurrence of degenerative diseases, such as cancer. This 
heterogeneous class of molecules, generally known as phytochemicals includes vitamins (carotenoids) 
and food polyphenols, such as flavonoids, phytoalexins, phenolic acids indoles and sulfur rich 
compounds [1–3]. More than 10,000 phytochemicals have been described, and among them more than 
6,000 compounds are included in the class of flavonoids [4]. They are widely present in plant derived 
foods and beverages (fruits, vegetables and beverage such as tea, wine beer and chocolate), and in 
many dietary supplements or herbal remedies. Due to the variety of their physiological roles in plant 
tissues in regulating enzymes involved in cell metabolism and in mechanisms of defence against 
foreign agents (radiations, viruses, parasites), phytochemicals have been associated to pleiotropic 
effects in animal cells. Phytochemicals attracted scientists’ interests since the demonstration that their 
biological targets in mammalian cells were the same involved in inflammatory processes and 
oncogenic transformation, such alterations of cell cycle control, apoptosis evasion, angiogenesis and 
metastases. In addition, a large number of epidemiological studies suggest that a daily intake of 
phytochemicals can reduce the incidence of several types of cancers [2,3,5,6]. However, we and others 
already underlined the discrepancy between phytochemical concentrations applied in in vitro studies 
(usually tens of micromolars) and those found in vivo (human and animal sera), after vegetable and 
fruit ingestion (usually below 1 M) [1]. The very low concentrations of free aglycones found in vivo 
are due to the scarce bioavailability and biotransformation of these molecules discussed in excellent 
reviews [7,8]. In fact, many phytochemicals, including polyphenols, are rapidly degraded and 
metabolized in the human body. Moreover, genetic variation in pathways affecting absorption, 
metabolism, and distribution of these natural substances, could influence exposure at the tissue level, 
thus modifying disease risk in individuals [9,10]. Nevertheless, this wide group of natural molecules 
represents a promising class as anticancer drugs, since their multiple targets in cancer cells, with 
limited toxic effect on normal cells. Phytochemicals can prove their therapeutic efficacy in   
mono-treatments or in association with classical chemotherapeutic drugs. In the latter case, a double 
positive effect can be expected: i. phytochemicals can synergize with cytotoxic drugs, increasing their 
efficacy and lowering the toxic side effects on normal cells; ii. combined treatment can delay 
resistance onset. 
Despite this encouraging preamble and the abundant literature describing the molecular 
mechanisms triggered by phytochemicals to inhibit cell growth and induce apoptosis in cancer cells, 
only few of them entered clinical trials. Here, we will focus our attention on a selection of 
representative molecules, namely isothiocyanate, curcumin, genistein, epigallocatechin gallate, 
lycopene and resveratrol, largely present in the literature. For each of them, we will summarize their 
putative mechanism(s) of action from in vitro and animal studies, and the current status of their clinical 
application in view of their realistic adoption as single chemotherapeutic agents or as 
chemosensitizers, in association with canonical and novel anti-cancer drugs. 
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2. Isothiocyanates 
Fruits and vegetables are important sources of secondary compounds that may supply nourishing 
health benefits beyond basic nutrition; examples of the latter are the glucosinolate products, such as 
sulforaphane (Table 1). Glucosinolates occur as secondary metabolites of many plants of the 
Brassicaceae family. Plants use substances derived from glucosinolates as natural pesticides and as 
defense against herbivores; these compounds are also responsible for the bitter or sharp taste of many 
common foods such as cabbage, mustard, horseradish, and Brussels sprouts. Glucosinolates are   
water-soluble anions and belong to the class of glucosides. All glucosinolates contain a central carbon 
atom which is bond, via a sulfur atom, to the glycone group, and, via a nitrogen atom, to a sulfonated 
oxime group. In addition, the central carbon is bond to a side group which confers specific to the 
molecule, since each glucosinolate has a different side groups (Table 1) [11]. More than   
120 glucosinolates are known to naturally occur in plants. They are synthesized from amino acids, 
such as methionine, phenylalanine, tyrosine or tryptophan. Plant enzyme myrosinase (-thioglucoside 
glucohydrolase), in the presence of water, hydrolyze the glucose group from glucosinolate leading to 
the quick formation of thiocyanates, isothiocyanates (ITCs) or nitriles. These are the active compounds 
employed by the plants against parasites. Even when plant myrosinase is completely inactivated by 
heat, the myrosinase activity of human intestinal bacteria allows the formation and absorption of   
ITCs [12]. However, the absorption and excretion of ITCs is substantially lower in cooked, compared 
to raw cruciferous vegetables [13]. 
ITCs are a heterogeneous family of molecules with the –N=C=S group as their common structural 
feature (Table 1). Unlike the glucosinolates, which are largely chemically stable and biologically inert, 
ITCs are electrophilic and biologically active. Vegetables contain different glucosinolate precursors, 
such as sinigrin (allyl isothiocyanate; AITC) in broccoli and Brussels sprouts; glucotropaeolin (benzyl 
isothiocyanate; BITC) in cabbage, gluconasturtiin (phenethyl isothiocyanate, PEITC) in watercress; and 
glucoraphanin (sulforaphane) (Table 1) in broccoli, Brussels sprouts, cabbage. 
A limited number of reports have dealt with their bioavailability [14]. To establish the blood 
concentration of sulforaphane in male rats after oral administration, the pharmacokinetics of 
sulforaphane was determined after a dose of 50 mol. The plasma drug concentrations occurred at 1 h 
and increased to a peak of around 20 M at 4 h after dosing. This concentration of sulforaphane offers 
clear relevance for numerous in vitro cell culture studies, where sulforaphane was typically employed 
at 1–30 M on a variety of in vitro signal transduction studies as well as phase II gene induction 
studies [15]. In a human study, ITC levels were determined in healthy volunteers after intake of 
vegetables. Sulforaphane levels were attained 1 h after consuming a broccoli soup with the molecule 
remaining still detectable in human plasma 24 h after [16]. Even if it is reasonable that repeated intake 
of vegetables may lead to higher plasma levels of ITCs, increasing its biological activity, Hanlon 
demonstrated that reiterated intake of broccoli does not determine sulforaphane accumulation in   
blood [17]. Dietary supplements containing extracts of broccoli sprouts, broccoli, and other cruciferous 
vegetables are available without a prescription. Some products are standardized to contain a minimum 
amount of glucosinolates and/or sulforaphane. However, the bioavailability of ITCs derived from these 
supplements is currently unknown. Toxins 2010, 2            
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Table 1. Chemical structure of selected phytochemicals 
1. 
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Table 1. Cont. 
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1 Structure were prepared using ChemSketch Freeware 12.0 from Advanced Chemistry Development (www.acdlabs.com). Toxins 2010, 2            
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Several animal studies of chemical induced carcinogenesis demonstrated that ITCs are able to 
inhibit cancer development (pre-initiation) [18]. However, very high intakes of PEITC or BITC   
(25–250 times higher than the average human intake of dietary ITCs) have been found to promote 
bladder cancer in rats when given after a chemical carcinogen (post-initiation) [19]. The relevance of 
these findings to human urinary bladder cancer is not clear, since at least one prospective cohort study 
found cruciferous vegetable consumption to be inversely associated with the risk of bladder cancer in 
men [20]. Many relevant biological effects of ITCs have been elucidated with respect to its anticancer 
properties. ITCs modulate events linked to clonal expansion in leukemia transformed cells, such as 
cell-cycle progression, apoptosis, and induction of differentiation. As an example, sulforaphane, at  
4 M concentration, caused 85% inhibition in U937 cell growth [21]. Two of the most abundant 
glucosinolates, sinigrin and gluconasturtin, which are hydrolyzed to AITC and PEITC, respectively, 
inhibited, in a dose-dependent manner, cell growth in HL-60 cell line (p53-null) with an IC50 of 2.56 
and 1.49 M, respectively. At 5 M concentration, PEITC induced caspase-8 activation in HL-60, 
during the initial 3 h of treatment [22]. BITC inhibited the benzo[a]pyrene-induced lung tumorigenesis 
in A/J mice [23], and reduced dramatically WEHI-3 leukemia cell viability with a sub-micromolar 
IC50, by causing G0/G1 arrest followed by apoptosis and caspase-3 activation [24]. Sulforaphane 
differentiated HL-60 into both granulocytes and macrophages, possibly by the involvement of 
PI3K/PKC [25]. 
ITCs are effective cancer chemopreventive agents [26]. In this contest, they generally act triggering 
detoxifying enzymes, thus blocking the initiation of carcinogenesis [27]. More recently, it has been 
demonstrated that oral feeding of synthetic isothiocyanate PHI (phenylhexyl isothiocyanate), at a dose 
of 12 mol/day, significantly reduced tumor formation in immunodeficient mice, with xenografts of 
human leukemia HL-60 cell, with no evidence of particular toxicity to normal tissue cells [28]. This 
work suggests that PHI may also act at the post-initiation level. The smaller weight of PHI-treated 
tumor was due to apoptosis. PHI inhibited the in vivo cell cycle progression through the down 
regulation of cyclin expression [28]. Many chemotherapeutic drugs, such as arsenic trioxide (ATO), 
possess a limited activity as a single agents in several hematological malignancies [29]. In a recent 
paper, incubation of leukemic cells in the presence of sulforaphane (3 M) combined with ATO   
(0.3 M) strongly enhanced ATO-mediated apoptosis [30]. Combination of ATO/sulforaphane therapy 
resulted in a significant intracellular ROS (Reactive Oxygen Species) increase. 
Despite substantial progress in the understanding of the molecular basis of anticancer activities of 
ITCs, very limited clinical studies on cancer patients have been reported. A phase I clinical trial is 
currently underway (Table 2). The goal of this study, approved but not yet active, is to determine the 
highest tolerable dose of PEITC to be administered to patients affected by lymphoproliferative 
disorder and treated with fludarabine. 
Finally, it must be mentioned that for some ITC compounds tumor promoting and carcinogenic 
activities have been described. As an example, oral administration PEITC and BITC induced 
continuous urinary epithelial cell proliferation leading to bladder carcinogenesis in rats. The induction 
of bladder lesions may arise from the hydrophobic activity of ITCs, depending on the alkyl carbon 
chain length [31]. A possible cytotoxic and genotoxic mechanism of ITCs in the urinary bladder 
involves the formation of intracellular ROS from N=C=S group and subsequent oxidative DNA 
damage [32]. Toxins 2010, 2            
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Table 2. Ongoing clinical trials testing dietary phytochemicals 
1. 
Trial Lead Organizations 
Therapy  
Phase  Type of cancer 
Polyphenol Other  treatments   
University of Texas - M.D. 
Anderson Cancer Center 
Phenethyl isothiocyanate  Fludarabine    I  Active  Lymphoproliferative disorders 
Mayo Clinic Cancer Center  17-AAG 
2 Gemcitabine    II  Active 
Recurrent Advanced Ovarian 
Epithelial or Primary Peritoneal 
Cavity Cancer 
Mayo Clinic Cancer Center  17-AAG 
2 Bortezomib    I  Active 
Advanced solid tumors and 
lymphomas 
Oregon Health and Science 
University - Knight Cancer 
Institute 
Broccoli sprout extract      II  Active 
Ductal carcinoma in situ and/or 
atypical ductal hyperplasia 
University of Texas - M. D. 
Anderson Cancer Center 
Curcumin
      II  Active  Advanced pancreatic cancer  
Rambam Medical Center  Curcumin  Gemcitabine    II  Active  Pancreatic cancer 
Tel-Aviv Sourasky Medical Center  Curcumin 
Gemcitabine and 
celecoxib 
 III  Active 
Advance or inoperable pancreatic 
cancer 
University of Texas - M. D. 
Anderson Cancer Center 
Curcumin 
Radiotherapy and 
capecitabine 
 II  Active  Rectal  cancer 
Tata Memorial Hospital  Curcumin  Ashwagandha extract
3  I/II  Active  Advanced  osteosarcoma 
Cleveland Clinic Taussig Cancer 
Center 
Curcumin  Boswellia serrata
4   II Active 
Newly diagnosed or recurrent 
high-grade gliomas 
University of Texas - M. D. 
Anderson Cancer Center 
Curcumin Bioperine      Completed  Multiple  Myeloma 
Johns Hopkins University  Curcumin      II  Terminated  FAP
5 
Memorial Sloan-Kettering Cancer 
Center 
Green Tea Extract      I  Completed  Advanced solid tumors 
Louisiana State University Health 
Sciences - Feist-Weiller Cancer 
Center 
Green Tea Extract      II  Active  Breast cancer progression Toxins 2010, 2            
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Table 2. Cont. 
UCLA - Jonsson Comprehensive 
Cancer Center 
Green Tea - Black tea      II  Active  Prostate adenocarcinoma 
University of Texas - M. D. 
Anderson Cancer Center 
Polyphenon E 
6     I  Closed  Breast  cancer 
University of Wisconsin - Paul P. 
Carbone Comprehensive Cancer 
Center 
Polyphenon E 
6     II  Active  Bladder  Cancer 
Barbara Ann Karmanos Cancer 
Institute 
Polyphenon E 
6     II  Active  MGUS
7 and Multiple Myeloma 
Mayo Clinic Cancer Center  Polyphenon E 
6     II  Active 
Chronic Lymphocytic Leukemia 
or Small Lymphocytic Lymphoma 
Louisiana State University Medical 
Center - Stanley S. Scott Cancer 
Center 
Polyphenon E 
6 Erlotinib
8   I/II  Active  NSLC 
9 
            
Aker Universitetssykehus HF  Syntetic Genistein (Bonistein)      II  Closed  Prostate cancer 
Northwestern University - Robert 
H. Lurie Comprehensive Cancer 
Center 
Genistein     II  Closed  Prostate  cancer 
Barbara Ann Karmanos Cancer 
Institute 
Genistein Gemcitabine    II  Completed  Breast  cancer 
University of North Carolina - 
Chapel Hill - Lineberger 
Comprehensive Cancer Center 
Genistein     I  Closed  Prostate  Cancer 
Robert H. Lurie Comprehensive 
Cancer Center at Northwestern 
University 
Genistein Interleukin-2    II  Closed 
Metastatic Melanoma or kidney 
cancer 
University of Wisconsin Paul P. 
Carbone Comprehensive Cancer 
Center 
Genistein     II  Closed  Bladder  cancer Toxins 2010, 2            
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Table 2. Cont. 
Barbara Ann Karmanos Cancer 
Institute 
Genistein 
Gemcitabine, and 
Erlotinib 
 II  Closed  Pancreatic  Cancer 
University of Minnesota - Masonic 
Cancer Center 
Genistein     I/II  Active  Osseous  Metastases 
Parker Hughes Cancer Center  Genistein immunoconjugate      I  Closed 
Recurrent B-cell Acute 
Lymphoblastic Leukemia or  
NHL 
10 
Barbara Ann Karmanos Cancer 
Institute 
Soy isoflavones      II  Closed  Adenocarcinoma of the Prostate  
H. Lee Moffitt Cancer Center 
CCOP Research Bas 
Soy isoflavones      NS  Closed  Breast cancer 
Barbara Ann Karmanos Cancer 
Institute 
Soy isoflavones  Radiotherapy    II  Closed  Prostate cancer 
Wake Forest University 
Comprehensive Cancer Center 
Soy isoflavones  Cholecalciferol    II  Active  Prostate cancer 
University of South Florida - H. 
Lee Moffitt Cancer Center and 
Research Institute 
Purified isoflavones      II  Active  Prostate Cancer 
Novogen, Incorporated  Phenoxodiol 
11      I  Completed  Refractory solid tumors 
Yale Cancer Center  Phenoxodiol 
11 Docetaxel    I/II  Active 
Ovarian epithelial, fallopian tube 
or primary peritoneal cavity cancer 
Marshall Edwards, Inc.  Phenoxodiol 
11     II  Active  Prostate  cancer 
            
University of Texas - M. D. 
Anderson Cancer Center 
Lycopene     II  Closed  Prostate  cancer 
H. Lee Moffitt Cancer Center and 
Research Institute 
Lycopene       Completed  Prostate  cancer 
University of Illinois Cancer 
Center 
Lycopene     NS  Closed 
Prostate cancer or benign prostatic 
hyperplasia Toxins 2010, 2            
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Table 2. Cont. 
North Central Cancer Treatment 
Group 
Lycopene      II  Completed  Metastatic prostate cancer 
USC/Norris Comprehensive 
Cancer Center and Hospital 
Lycopene Supplements
12     II  Active  Recurrent prostate cancer 
Toronto Western Hospital  Lycopene  Antioxidants
13     II  Active  Early stage prostate cancer 
Toronto Western Hospital  Lycopene  Antioxidants
13   II  Active  Prostate  cancer 
Ohio State University Medical 
Center - Arthur G. James Cancer 
Hospital and Solove Research 
Institute 
Tomato-Soy Juice      I/II  Active  Prostate cancer 
Chao Family Comprehensive 
Cancer Center at University of 
California Irvine Medical Center 
Resveratrol     I/II  Closed  Colon  Cancer 
University of Michigan - 
Comprehensive Cancer Center 
Resveratrol     I  Active  Resectable colorectal cancer 
GlaxoSmithkline SRT501
14     I  Active 
Colorectal cancer and hepatic 
metastases 
GlaxoSmithkline SRT501
14 Bortezomib    II  Active  Multiple  Myeloma 
1 Deducted primarily from http://www.cancer.gov/clinicaltrials; 
2 17-N-allylamino-17-demethoxygeldanamycin; 
3 Ingredients from traditional Indian medicine with potent 
anti-cancer compounds in laboratory as well as animal studies; 
4 Extracts of Boswellia serrata are used in traditional herbal medicine in India and in African countries. 
Animal experiments show anti-inflammatory activity of the extract; 
5 Familial Adenomatous Polyposis; 
6 A decaffeinated green tea catechin mixture containing about 50% 
EGCG and 30% other catechins; 
7 Monoclonal Gammopathy of Undetermined Significance; 
8 EFGR tyrosine kinase inhibitor; 
9 Non-Small Cell Lung Cancer; 
10 Non-
Hodgkin's Lymphoma; 
11 Synthetic genistein; 
12 contains vitamin D3, vitamin E, selenium, green tea extract, saw palmetto, lycopene, and soy derivatives; 
13 vitamin E, 
selenium and lycopene; 
14 SRT501 is a proprietary chemical developed by Sirtris based on the naturally occurring resveratrol; NS, not specified. Toxins 2010, 2            
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3. Curcumin 
Curcumin is a polyphenol (bis--unsaturated diketone, commonly called diferuloylmethane) 
derived from the rhizome of Curcuma longa (Table 1), also called turmeric, which belongs to the 
Zingiberaceae family. This perennial herb is cultivated in Asiatic countries, mainly in India and China. 
The yellow-pigmented fraction of turmeric contains curcuminoids: curcumin (curcumin I, that is the 
main component), demethoxycurcumin (curcumin II), bisdemethoxycurcumin (curcumin III), and 
cyclocurcumin. Curcuminoids are chemically related and represent 3%–5% of turmeric [33]. 
Traditionally, turmeric and natural curcuminoids have been used in folk medicine for its   
therapeutic effects, like antioxidant, anti-inflammatory, anticancer, antimicrobial, hepatoprotective, 
thrombosuppressive, hypoglycemic, antiarthritic. These therapeutic effects have been investigated and 
partially confirmed [34,35]. The anticancer properties of curcumin originate from several papers 
showing that the molecule can induce apoptosis in different cancer cell lines and inhibit the formation 
of tumours in animal models of carcinogenesis. The anti-carcinogenic activities of curcumin have been 
attributed to its effects on several targets including transcription factors, growth factors and their 
receptors, cellular signaling molecules, genes regulating cell proliferation and apoptosis, adhesion 
molecules and regulators of angiogenesis [36]. These pleiotropic activities derive from the complex 
chemistry of the molecule (unsaturation in the side chain methoxy groups in the benzene ring and 
central  -diketone moiety) which influences multiple signaling pathways by direct interaction or 
through modulation of gene expression [37]. 
The anti-carcinogenic effects of curcumin on pancreatic cancer have been initially demonstrated in 
a variety of pancreatic cell lines, where the molecule suppresses proliferation and induces apoptosis 
through down-regulation of constitutively active NF-B and IB kinase [38]. In pancreatic cell line, 
curcumin also inhibits cell growth by down-regulation of COX-2, EGFR, ERK1/2 [39]. The in vitro 
anticancer properties have been also confirmed in in vivo studies. In murine xenograft models, 
pancreatic cancer cells were subcutaneously injected into nude mice and intravenous administration of 
liposomal curcumin caused reduction of tumor size and decrease of CD31, VEGF and IL-8   
expression [38]. In addition, a combination of curcumin and gemcitabine inhibited pancreatic cancer 
growth in nude mice better than gemcitabine alone, suggesting chemosensitizing effect of the   
molecule [40]. A large number of clinical trials have been performed to investigate the 
pharmacokinetics, safety and efficacy of curcumin, to show its therapeutic potential against different 
cancers including leukemia and lymphoma, gastrointestinal cancer, genitourinary cancer, breast 
cancer, pancreatic cancer, lung cancer, melanoma, neurological cancer and others [36,41]. Clinical 
trials on patients affected by advanced pancreatic cancer, familiar adenomatous polyposis (FAP), and 
multiple myeloma (MM) are obtaining promising results (Table 2). Curcumin efficacy in the treatment 
of human pancreatic cancer has been reported in a phase II clinical trial in patients affected by 
advanced pancreatic cancer [42]. Twenty-five patients were enrolled and twenty-one were evaluable 
for response. A dose of 8 g/day of curcumin was administered orally until disease progression, with 
restaging every 2 months. In PBMC (peripheral blood mononuclear cells) of patients who received 
curcumin has been noted down-regulated expression of NF-B, COX-2 and phosphorylated STAT3. In 
two patients, antitumor effects of curcumin was observed; one had ongoing stable disease for more 
than 18 months and one had 73% tumor reduction, but he was short-lived. In this latter patient, a rapid Toxins 2010, 2            
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and dramatic increase in serum cytokine levels (release of cytokines from the tumor has associated 
with shrinkage) was detected. This study showed that oral curcumin is well tolerated without toxicity 
at doses of 8 g/day for up to 18 months. Low levels of curcumin was measured in the plasma (steady-
state level at day 3 was 22–41 ng/mL), but, although the molecule was poorly absorbed, a limited 
number of patients (9.5%) beneficed of the positive effects of curcumin [42]. It is well-known that 
curcumin in vitro show antiproliferative effects when used to micrograms amounts [38]. Therefore, the 
limited bioavailability of curcumin probably attenuated the response rate. 
A significant number of studies describe the antiproliferative mechanism of curcumin against MM. 
In four different MM cell lines (U266, RPMI 8226, MM.1, and MM.1R), curcumin blocked the 
constitutively active IKK and inhibited NF-B activation, leading to the suppression of proliferation 
and induction of apoptosis [43]. Moreover, the molecular consequence of NF-B suppression by 
curcumin was the reduced expression of several gene products regulated by NF-B, such as IB, Bcl-
2, Bcl-XL, IL-6, and cyclin D1 [43]. In other MM cells, curcumin inhibited IL-6 induced STAT3 
phosphorylation and consequent STAT3 nuclear translocation, playing an important role in the 
suppression of MM proliferation [44]. Curcumin can overcome chemoresistance and enhance the 
activity of thalidomide and bortezomib, used to treat patients with MM, both in vitro and in a 
xenograft model in nude mice [45]. These results on experimental models have been confirmed in a 
promising phase I/II study where curcumin was administered to MM patients at growing concentration 
of 2, 4, 8, 12 g/day, orally. All doses were well tolerated without adverse events. Curcumin inhibited 
constitutive activation of NF-B, COX-2 and STAT3 in the PBMC isolated from MM patients. 12 out 
of 29 patients continued the treatment for 12 weeks and five of them completed one full year of 
therapy with stable disease [46]. 
Several studies on a variety of colorectal cell lines indicate that curcumin might be employed as 
therapeutic agent against several molecular targets. As largely reviewed by others, in these cellular 
model, curcumin inhibits NF-B activation, neurotensin-mediated activator protein-1, Ca
2+ 
mobilization, PGE-2 (prostaglandin E2) and epidermal growth factor receptor (EGF-R) and   
down-regulates COX-1/2, MMP-2/9, IL-8 gene induction and colon cancer cell migration [47,48]. The 
potential use of curcumin as chemotherapic agent against colorectal neoplasia is also supported by 
animal studies and human clinical trials. In murine models induced with azoxymethane, curcumin 
inhibited the incidence of colonic adenocarcinomas and adenomas [49]. In Min mice, a murine model 
of FAP, curcumin significantly decreased tumor formation of 64% [50]. Oral administration of 
curcumin in cancer patients resulted in an increased concentration in colon tissue to approximately  
10  mol/kg, suggesting that oral curcumin can induce apoptosis in the gastrointestinal tract   
efficiently [51]. In a positive, but small clinical trial, the ability of curcumin to induce adenoma 
regression in five patients with FAP previously colectomized was evaluated [52]. The authors used an 
oral combination treatment including 480 of curcumin and 20 mg of quercetin three times a day for a 
mean duration of six months. All five patients had a significantly decreased number and size of ileal 
and rectal adenomas from baseline (60.4% and 50.9%, respectively), without producing any 
appreciable toxicity. The authors concluded that the putative anticancer mechanism(s) of curcumin in 
adenoma regression in FAP patients probably include up-regulation of carcinogen-detoxifying 
enzymes such as glutathione S-transferases, antioxidation, and suppression of the isoenzyme COX-2, 
and decrease in inducible PGE-2 [52]. Toxins 2010, 2            
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There anticancer properties of curcumin are reinforced by the observation that, in many cases, the 
molecule kill tumor cells without damaging normal cells [53]. However, others suggest that curcumin 
may cause toxicity under specific conditions. A possible mechanism is that low concentrations of 
curcumin induce antioxidant effects, higher concentrations of this compound increase the cellular 
levels of ROS [54,55]. The main problem in the therapeutic use of the molecule remains its limited 
bioavailability. The low plasma and tissue levels of curcumin appear to be due to poor absorption, 
rapid metabolism, and rapid systemic elimination. To improve the bioavailability of curcumin, 
numerous approaches have been evaluated: (i). combination with an adjuvant like piperine, which 
interferes with glucuronidation; (ii). liposomal curcumin; (iii). curcumin nanoparticles; (iv). curcumin 
phospholipids complex; v. structural analogs of curcumin [56]. 
Table 2 reports clinical trials in active phase where curcumin is tested in monotherapy or combined 
with natural extracts in the treatment of pancreatic cancer, colorectal cancer, FAP, MM, glioma and 
osteosarcoma. Hopefully, results of these studies will be shortly available and will provide further 
evidence of the therapeutic efficacy of the molecule. 
4. Genistein 
Isoflavones, a sub-class of flavonoids, have a limited distribution in nature, and soyfoods are the 
only nutritionally relevant dietary source of these phytochemicals especially in Asian population 
where they provide 10% of total individual protein intake. There is a growing body of epidemiological 
studies suggesting that genistein (4',5,7-trihydroxyisoflavone) the predominant isoflavone in the plant 
family Leguminosae, which includes the soybean, may be helpful in preventing and treating several 
types of cancers, principally breast and prostate cancers [57–59]. Several mechanisms for the in vitro 
anti-cancer effects of genistein have been proposed [60]. Since the molecular structure of genistein 
(Table 1) and related compounds closely resembles those of estrogens, this group of molecules is also 
known as “phytoestrogen”. Genistein competes with 17--estradiol (E2) in Estrogen Receptor (ER) 
binding assays [61]. Its binding affinity is higher (87%) for ER than for ER. ERs mediate the 
actions of hormone in different estrogen-dependent tissues, such as uterus, ovary and breast, where the 
levels and ratios of the two receptors are known to vary substantially. For example, ERα is the 
predominant form found in uterus and liver, whereas ERβ is mainly expressed in ovary. ERs also 
mediate the actions of estrogens and selective ER modulators in breast cancers, where 70% express 
ERβ form. The presence of ERα is associated with the proliferative effects of estrogens, whereas it is 
known that ERβ possesses growth-suppressive activities. 
In vitro studies demonstrated that genistein inhibits growth of most types of hormone-dependent 
and -independent cancer cells and its effects on cellular signaling are dose depending [62]. In fact, it 
has been reported that preferential activation of ERβ by genistein is lost when genistein is increased 
from low (6 nM) to higher concentrations. At 300 nM, genistein activates both ERs; therefore, the final 
effect on gene expression and cell fate depends on ligand dose, and on the differential ability of  
ligand-ER complexes to recruit modulators at the ER binding sites of hormone-regulated genes [62]. 
Reasonably, the antiproliferative activity of genistein at concentrations higher than 10 μM is mediated 
by tyrosine kinase (PTK) inhibition. In fact, genistein is a potent in vitro inhibitor of PTKs activity, 
especially EGF-R [63]. This led to the suggestion that genistein might exert in vivo anticancer effects Toxins 2010, 2            
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by inhibiting the activity of EGF-R PTK, or those of other PTKs, such as HER-2 [64]. In addition, 
similarly to other flavonoids (e.g., quercetin), genistein triggers regulative pathways under the control 
of MAPK, AKT and NF-B [60]. Cell culture data indicate that genistein inhibits prostate specific 
antigen expression (PSA) in androgen-dependent and independent prostate cancer cell lines [65] 
supporting the role of genistein as a chemopreventive/therapeutic agent for prostate cancer irrespective 
of androgen responsiveness. 
Both in vitro and epidemiological studies showing anticancer properties of genistein have been 
confirmed by in vivo data obtained on animal models. These studies utilize genistein in different 
formulas. Standard soy isoflavone formula contains genistein mainly in the form of genistein 
(genistein monoglycosides), as well as other isoflavones (daidzin and glycitin). The percentage of 
different isoflavones present in this soy formula correlates with the amount of the same compounds 
found in soybeans, i.e., 50% genistein, 38% daidzin, and 12% glycitin. A 50 mg dose of soy 
isoflavones (a typical daily dose) provides 25 mg of genistein, 19 mg of daidzin and about 6 mg of 
glycitin. Pharmacologic research has developed also synthetic genistein analogs. The most 
representative are 1-bonistein and 2-phenoxodyol. 1-Bonistein is a pure synthetic genistein, developed 
by DSM Nutritional Products (Basel, Switzerland) consisting in 99.4% synthetic genistein aglycone. It 
has been tested in healthy volunteers in phase I clinical trial to assess safety and tolerability [66]. 
Tolerability of different doses (from 30 to 300 mg) was good and uptake was also very rapid, as 
revealed by plasma concentration-time course. Mean Cmax values of 252.0, 605.0, 1,518.0, and   
1,808.0 ng/mL were observed in the 4–6 h range. Bonistein is actually evaluated in an active clinical 
trial in patients who are undergoing surgery for prostate cancer (Table 2). 2-Phenoxodyol is a synthetic 
isoflavone with 1,2 diphenylpropane-ring structure (Table 1) characterized by a more pronounced 
antineoplastic activity with reduced toxicity in cancer-derived cell lines and animal models [67]. It was 
tested in phase I/II clinical trial by continuous intravenous infusion in patients with solid cancer. This 
study demonstrated that a seven-day continuous infusion of phenoxodiol given every two weeks 
showed no severe toxicity up to a dose of 27.0 mg/kg/day [68]. Moreover, a recent study employed 
phenoxodiol to sensitize chemoresistant ovarian cancer cells to platinum and taxane drugs, as well as 
gemcitabine and topotecan [67]. The importance of this study is underlined by the interest of FDA 
(Food and Drug Administration, USA) to accelerate researches for the therapeutic use of phenoxodiol 
as chemosensitizer in platinum- and taxane-based chemotherapy to cure recurrent ovarian cancer [67]. 
More than a decade ago, in vivo animal models of carcinogenesis revealed the chemopreventive 
effects of genistein (or isoflavone rich diet) [69,70]. In recent in vivo studies, the efficacy of 
genistein/isoflavone as sensitizing agent in association with chemotherapeutic drugs was also   
reported [71,72]. Earlier in 1992, soy containing diets was demonstrated to reduce the severity of 
prostatitis in rats and prevented prostate adenocarcinoma in rat carcinogenesis models [69,70]. In 
PTEN (phosphatase and tensin homolog) heterozygous (+/-) mutant mice (mPTEN), a model for 
endometrial carcinoma, it was shown that genistein inhibited PTEN-related tumorigenesis [73]. In a 
different study, it was reported that soy-derived isoflavones (0.1 mg/day given intra-peritoneally) 
significantly inhibited growth of T-ALL (T-cell Acute Lymphoblastic Leukemia)-derived cell lines 
and their infiltration into various organs in NOD/SCID (severe combined immunodeficient) mice [74]. 
However, in a rat model of colon cancer, adverse effects of genistein have been reported [28]. The 
results of this study “emphasize that the biological effects of genistein may be organ specific, Toxins 2010, 2            
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inhibiting cancer development in some sites yet showing no effect or an enhancing effect on the 
tumorigenesis at other sites, such as the colon” [28]. Despite this negative observation, strong 
experimental data support the protective effects of genistein mainly in prostate and breast cancers. 
In combination therapy, genistein significantly enhances the antitumor, anti-invasive, and   
anti-metastatic activities of chemotherapeutic drug docetaxel, both in cell lines and in a murine model 
of experimental prostate cancer bone metastasis [38]. The authors demonstrated that enhancement of 
docetaxel efficacy by genistein involves OPG/RANK/RANKL/MMP-9 pathway and results in the 
inhibition of osteoclastic activity and prostate cancer bone metastasis. Using the PC-3 orthotropic 
metastatic mouse model, it was shown that soy isoflavones and irradiation leads to enhanced control of 
primary tumor growth and metastasis in prostate tumors [75]. These results suggest that therapy against 
prostate cancer might benefit from genistein treatment when associated to docetaxel or radiotherapy. 
From data reported above, convincing evidence emerge on the promising therapeutic applications of 
genistein in cancer therapy. However, the double-faced behavior of the molecule, inhibition of cell 
proliferation at high concentrations and activation of estrogen-dependent effects at low concentrations, 
requires caution in determining therapeutic doses in mono-treatment or in combination with 
chemotherapy, radiotherapy, and immunotherapy. It is reasonable that, at low concentration, genistein 
may enhance cytotoxicity of conventional anticancer therapy limiting the harmful side effects often 
observed in patients treated with massive doses of radiotherapy or cytotoxic drugs. This is the main 
goal in modern cancer therapy currently under investigation in different clinical trials. Actually,   
16 clinical trials for genistein and 28 for isoflavone are running on patients affected by a variety of 
cancers, including breast, prostate cancers, melanoma, kidney, pancreatic cancers and leukemia   
(a selection of them is reported in Table 2). Previous phase I clinical trials assessed safety, 
pharmacokinetic parameters and efficacy of orally administrated isoflavones [76–78]. These studies 
demonstrated that soy isoflavone, or purified soy isoflavone mixture (genistein, daidzein and glycitin), 
were not toxic, nor genotoxic. In subjects with prostate cancer, plasma concentration of genistein after 
oral administration (150 mg) ranged from 4.3 to 16.3 M, a dose compatible with its biological activity 
in vitro [76]. However, in a significant percentage of PBMC isolated from patients (77%–78%), the 
authors observed an increase in the pattern of tyrosine phosphorylation after 6 hr of genistein 
ingestion, when its plasma concentration was elevated. The predominant band showed a molecular 
weight of about 60 kDa [76]. This study reflects the potential opposing effects associated to the same 
molecule depending on the in vitro versus in vivo experimental model. 
To confirm the in vivo chemopreventive efficacy of genistein, the molecule was given as dietary 
supplement in a clinical trial in women at high risk for breast cancer. Other clinical trials are recruiting 
subjects to study genistein as dietary supplementation in treating patients undergoing radiotherapy for 
bone metastasis and in patients who are undergoing surgery for bladder cancer. Aim of these studies is 
to prevent cancer recurrence after surgery or radiotherapy using genistein as dietary supplement. 
Active but not still concluded clinical trials are using dietary supplement of genistein as promising 
sensitizer agent associated with interleukin-2 in patients with metastatic melanoma or kidney cancer 
and in association with gemcitabine and erlotinib (TK inhibitor) in patients with locally advanced or 
metastatic pancreatic cancer (Table 2). Isoflavone genistein, given as dietary supplement, is under 
investigation in patients with stage II, III or IV prostate cancer and combined with gemcitabine in 
treating women with stage IV breast cancer. These studies are completed even if there are no published Toxins 2010, 2            
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results. However a phase II clinical study, to investigate modulation of serum PSA levels in patients 
with prostate cancer after soy isoflavone supplementation (Novasoy), showed a decline of serum PSA 
levels without any toxicity [79]. Finally, an interesting approach has been adopted in an active clinical 
trial using a B43-genistein immunoconjugate. Similar strategies may optimize genistein specific 
targets in leukemia cells, without toxicity in normal, non transformed cells. This trial is recruited 
patients with recurrent ALL and Non-Hodgkin’s Lymphoma (NHL). When conjugated to B43 
monoclonal antibody, genistein is able to target B-lineage leukemia that unlike normal cells,   
over-expresses the target antigen CD19 [80]. Genistein is also conjugated to recombinant EGF to 
target cancers over-expressing the EGF receptor as in breast cancer [81]. 
5. (-)-Epigallocatechin-3-gallate (EGCG) 
Tea, produced from leaves of Camelia sinensis is one of the most popular beverages worldwide and 
a natural dietary source of polyphenols, mainly catechins. (-)-Epigallocatechin-3-gallate (EGCG) is the 
most bioactive green tea catechin, as demonstrated in several cell culture studies [82], animal models 
and epidemiological evidences [83] (Table 1). 
To date, the large number of studies on the anticancer properties of EGCG regards its 
chemopreventive effects. Similarly to other phytochemicals, EGCG modulates different signaling 
pathways responsible for its chemopreventive and potential chemotherapeutic activity against cancer 
cells. EGCG, like other flavonoids, is a prototype of phytochemical with multiple effects on   
intra-cellular signaling. Its antioxidant effects in protecting against oxidative damage of DNA, lipids 
and proteins, potentially associated with cancer development, has been largely investigated [82]. 
However, this issue is partially controversial. In fact, EGCG significantly reduces plasma levels of 
oxidative biomarkers in animal models, but limited efficacy has been proved in humans [84,85]. 
Moreover, ROS production in cell culture medium by EGCG promoted DNA damage in rodent 
macrophage-like RAW 264.7 and human promyelocytic leukemic HL-60 cell lines. These pro-oxidant 
effects of the molecule are dose dependent since human lymphocytes treated with low concentration 
(from 10
−8 to 10
−5 M) are protected against DNA strand breakage, while the opposite occurs with high 
doses of EGCG (10
-3M) [86]. This study is a further example of controversial results when in vitro and 
in vivo studies involving natural phytochemicals are compared. In this respect, a recent review 
suggested a causal association between green tea and liver damage [38]. The hepatotoxicity must 
probably be attributed to EGCG or its metabolites which, under particular conditions related to the 
patient's metabolism, can induce oxidative stress in the liver [38]. Serum concentrations of EGCG 
achieved after tea drinking range between 0.1–1 M [87], a dose associated with a pro-apoptotic 
effects in human B-CLL (B-cells chronic lymphocytic leukemia) [88], even if tens micromolar 
concentration of EGCG are usually necessary in cell culture studies to observe pro-apoptotic effects. 
To explain the multiple biochemical targets for tea polyphenols in cell culture studies, it has been 
speculated that catechins have functional and structural similarity with chaperones: in silico studies 
revealed several conformations of EGCG, (-)-epicatechin gallate and (-)-epigallocatechin able to 
interact with cellular components (double strand DNA, RNA, lipids and proteins) [89]. In particular, 
direct EGCG interactions with nucleic acids are confirmed by surface plasmon resonance assay and 
cold spray ionization-mass spectrometry [90]. Toxins 2010, 2            
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Induction of apoptosis and cell cycle arrest by EGCG is shown in different transformed cell lines, 
derived from solid tumors (lung, colon, pancreas, and skin) and human leukemia, without affecting 
normal cells. These biological activities are explained by direct or indirect inhibition of different 
tyrosine and serine-threonine kinases involved in cell cycle regulation or apoptosis (cyclin-dependent 
kinases, membrane receptors EGF-R/HER-2, VEGF-R1/R2, IGF/IGF-1, cytoplasmic kinases 
PI3K/AKT and MAPK) [82]. Recently, 67 kDa laminin receptor (67LR) has been identified as a cell 
surface receptor for EGCG that mediates its anticancer activity. Indeed, expression of 67LR confers 
EGCG responsiveness to tumor cells, without affecting normal cells, like fibroblasts or PBMC [15]. 
These authors demonstrated that EGCG induced the disruption of stress fibers and decreased the 
phosphorylation of the myosin II regulatory light chain (MRLC) at Thr18/Ser19, which is necessary 
for cell division. Cancer cells were transfected with short hairpin RNA (shRNA) expression vector to 
downregulate 67LR expression. When the 67LR was silenced, the suppressive effect of EGCG on the 
MRLC phosphorylation was significantly attenuated. These results suggest that EGCG inhibits cell 
growth by reducing the MRLC phosphorylation and this effect was mediated by 67LR [91,92]. 
Using
  a combination of nuclear magnetic resonance, binding assays,
  fluorescence polarization 
assay, and computational docking studies,
 Leone et al. found that EGCG and black tea theaflavins
 are 
very potent inhibitors (Ki in the nanomolar range) of the
 anti-apoptotic factors, Bcl-XL and Bcl-2, 
suggesting a direct binding of EGCG to the in BH3 pocket of these proteins, at concentrations very 
close to physiological plasma levels, supporting a realistic use of EGCG as anticancer and   
pro-apoptotic drug in humans [93]. On the other hand, a recent study by Golden et al. [94] revealed a 
side effect of EGCG as an antagonist of bortezomib, a novel proteasome inhibitor in clinical use for 
MM. This result indicates that green tea polyphenols can be able to block the therapeutic efficacy of 
some anticancer agents and suggest that consumption of green tea products may be contraindicated 
during cancer therapy with bortezomib. 
In commenting the clinical and preclinical studies based on EGCG administration, it is necessary to 
underline that a clear cause-effect relationship between amounts of green tea supplemented and 
protective effects has not been established. Most studies tested green tea in the form of a brewed 
beverage, rather than in capsule form. One cup of tea contains approximately 50 mg of caffeine and 
80–100 mg of polyphenol content, depending on the strength of the tea and the size of cup. Many 
studies examined the effects of habitually drinking anywhere from 1–10 cups per day (or greater). In 
capsule form, there is considerable variation in the amount of green tea extract (GTE), ranging from 
100 to 750 mg per capsule. Currently, there is no established recommended dose for GTE capsules. 
Polyphenon E, (decaffeinated green tea catechin mixture) prepared with a standardized dose of EGCG, 
is usually administered in the range of 0.4–2 g twice a day to 3–6 subjects per dose level. 
Initial studies utilizing green tea polyphenols extract (GTP) have focused on the potential 
chemopreventive activity of EGCG in animals and humans. Earlier in 1992, an anti-skin tumor-initiating 
effect of EGCG was reported in Sencar mice [95]. The application of EGCG before challenge with 
7,12-dimethylbenz[a]anthracene as tumor initiator, resulted in significant reduction both in percentage 
of mice with tumors and number of tumors per mouse compared with controls. Direct application of 
GTP in humans prevented ultraviolet (UV)-B-induced cyclobutane pyrimidine dimers, considered to 
be mediators of UVB-induced immune suppression and skin cancer induction [96]. In combination 
protocols with conventional chemotherapeutic drugs, tamoxifen plus EGCG showed a synergistic Toxins 2010, 2            
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cytotoxic effect towards ER-negative breast cancer cells [97]. In athymic nude female mice implanted 
with MDA-MB-231 breast cancer cells, the same treatment reduced tumor volume of 71% compared 
with vehicle control, whereas tumor weight was decreased by 80% [97]. Given these promising results, 
a phase I clinical trial has been conducted to prove the effectiveness of GTE in patients with advanced 
solid tumors who were refractory to standard therapy (Table 2). A different phase II clinical trial, 
actually ongoing, is testing the effect of Polyphenon E administration on tumor cell of breast cancer 
patients in the interval between biopsy and surgery. The investigators’ primary objectives are to 
determinate the molecular effects of Polyphenon E in breast tumor cells such as c-Met oncogene 
expression/phosphorylation levels and PI3K and MAPK activations. Secondary objectives include 
serum biomarkers and effects on other tissues. Evaluation of the safety and tolerability of Polyphenon 
E in these subjects represent an additional aim to be pursued (Table 2). A different study is actually 
recruiting patients with breast cancer. The investigators hypothesize a reduction in proliferation and/or 
an increase in apoptosis in cancer cells after a short-term treatment with EGCG. This clinical trial is 
testing the beneficial effects of green tea (capsule) in biopsy tissues. Green Tea Catechins (GTCs) 
administration to TRAMP mice, a model of spontaneous development of prostate cancer, results in a 
substantial delay of tumor progression in 80% of the animals [98]. Based on this evidence, oral 
administration of GTCs (600 mg/die) in men with high grade prostate intraepithelial neoplasia resulted 
in only 3% development of prostate cancer after one year of follow up in men taking EGCG capsule, 
compared to 30% treated with placebo [99]. The same authors identified by qPCR an 8-genes signature 
that significantly discriminated benign tissue from prostate cancer in both humans and TRAMP mice 
model [99]. Chow et al. [100] performed a phase I pharmacokinetic study to determine the systemic 
availability of green tea catechins after single oral dose administration of EGCG and Polyphenon E in 
20 healthy subjects (five subjects/dose level), randomly assigned to one of the dose levels (200, 400, 
600, and 800 mg based on EGCG content). They reported no significant differences in the 
pharmacokinetic characteristics of EGCG at 800 mg dose versus Polyphenon E administration. The 
authors concluded that the two catechin formulations resulted in similar plasma EGCG levels. Based 
on these pre-clinical studies, Pisters et al. [101] designed a phase I Trial to determine the   
maximum-tolerated
  dose, toxicity, and pharmacology of GTE
  in 49 patients with solid tumors.   
Dose-limiting toxicities
 were caffeine related and included neurologic and gastrointestinal
 effects. The 
maximum-tolerated dose of GTE was 4.2 g/m
2 once daily,
 or 1.0 g/m
2 three times day. No major 
responses occurred. Ten patients with stable disease completed six months of GTE. They concluded 
that a dose of 1.0 g/m
2 (equivalent to 7–8 Japanese
 cups consisting of 120 ml of green tea three times 
daily) can be recommended
 for further studies. A phase II clinical trial was conducted by the North 
Central Cancer Treatment Group [102] which evaluated 42 patients manifesting progressive PSA 
elevation with hormone therapy (androgen independent metastatic prostate carcinoma). Patients 
received 6 gr/day of green tea in 6 divided doses. They were monitored monthly for response and 
toxicity. A single patient showed tumor response, defined as a decline ≥50% in the baseline PSA 
value. This response was not sustained beyond two months. At the end of the first month, the median 
change in the PSA value from baseline for the cohort increased by 43%. Green tea toxicity (nausea, 
emesis, insomnia, fatigue, diarrhea, abdominal pain, and confusion) occurred in 69% of patients. In a 
recent study involved 26 men with positive prostate biopsies and scheduled for radical prostatectomy, 
patients were treated with daily doses of Polyphenon E (800 mg of EGCG for a total of 1.3 g of tea Toxins 2010, 2            
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polyphenols) before radical prostatectomy occurred. Serum biomarkers (hepatocyte growth factor, 
HGF; vascular endothelial growth factor, VEGF; insulin-like growth factor, IGF-I; IGF binding 
protein-3, IGFBP-3; and PSA) were analyzed before initiation of the study and on the day of 
prostatectomy. The results support a potential role for Polyphenon E in the treatment (or prevention) of 
prostate cancer because the authors found significant reduction in serum levels of PSA, HGF, and 
VEGF [103]. Shanafelt et al. conducted a study on clinical effects of oral GTE administration in six 
patients with low grade B-Cell malignancies [104], reporting a positive response in four subjects 
shortly after “self-initiating” GTE therapy. Therefore, the same group started a phase I/II study 
enrolling 33 previously untreated patients with asymptomatic Rai stage 0 to II CLL to test the efficacy 
of Polyphenon E [105]. Patients who received Polyphenon E with a standardized dose of EGCG (range 
400 to 2,000 mg/day) evidenced minor adverse effects with one patient obtaining partial remission. In 
addition, 11 patients (33%) showed a 20% reduction in absolute lymphocyte count, and 11 out of  
12 (92%) patients with palpable adenopathy experienced at least a 50% reduction of all nodal areas 
during treatment. After one month of treatment, plasma EGCG levels ranged from 2.9 to 3.9 ng/mL. 
This encouraging study anticipated a phase II clinical trial to evaluate efficacy of EGCG at 2,000 mg 
dose, twice a day (Table 2). A phase II clinical trials with Polyphenon E (800 to 1,200 mg EGCG daily 
for 14–28 days) was also sponsored by University of Wisconsin in patients with non metastatic bladder 
cancer to compare levels of EGCG in non malignant bladder tissue versus malignant bladder tissue in 
these patients (Table 2). Secondary objective was the dose–response modulation of surrogate-endpoint 
biomarkers (e.g., PCNA, MMP2. clusterin, VEGF, p27) in malignant and non malignant samples of 
bladder tissues and changes in serum levels of IGF-1 and IGFBP-3 after administration of Polyphenon 
E. No results have been published yet. Finally, a phase II randomized trial is evaluating the effects of 
six cups of green tea and decaffeinated black tea versus water in 180 patients with prostate 
adenocarcinoma scheduled to undergo prostatectomy (Table 2). This study aimed to compare levels of 
prostate cancer biomarkers (PSA) versus tumor development and progression assessed by biopsy. 
Genotype and gene expression of metabolizing enzymes (COMT, UGT and SULT) have been also 
evaluated in patients biopsies. Results are not available yet. Given the potential of Polyphenon E to 
improve chemotherapeutic drugs effects, a phase I/II clinical Trial was initiated in patients with 
advanced non small cell cancer (NSCLC) treated with novel drug Erlotinib (EGFR/TyrK inhibitor). 
Combination of Erlotinib with Polyphenon E will be evaluated also in preventing cancer recurrence in 
former smokers who have undergone surgery for bladder cancer. This trial is enrolling patients (Table 2). 
6. Lycopene 
Lycopene (-carotene) is the most abundant carotenoid in tomato Lycopersicon esculentum L. 
From a chemical point of view, it is a tetraterpene hydrocarbon extremely lipophlic (Table 1) 
synthesized by plants and some microorganisms [106]. In nature, lycopene is essentially present as  
all-trans-isomer. However, the instability of double bounds to light, heat or chemicals induces 
isomerization [107,108] with the production of a mixture of cis-isomers which are commonly found in 
human serum and tissues [106,109]. Differently than other plant carotenoids possessing vitamin A-like 
function for the presence of the b-ionone ring, lycopene, lacking this structure, does not have known 
physiological function in humans, except for its strong antioxidant activity. In fact, the molecule is Toxins 2010, 2            
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able to efficiently quench singlet oxygen (
1O2) because the presence of several conjugated double 
bonds [110], and to scavenge free radicals. It has been demonstrated that a single lycopene molecule 
can scavenge more than one ROS, due to the presence of the long polyene chain [111]. The antioxidant 
properties of lycopene have been largely proved in cell culture at micromolar concentrations on several 
targets, including nitration of protein, DNA damage by hydrogen peroxide and peroxynitrite. In addition, 
lycopene has been reported to up-regulate the ARE (antioxidant response element)-dependent 
transcription of antioxidant enzymes, such as superoxide dismutase-1, catalase, epoxide hydrolase and 
transferrin under the control of Nrf2 transcription factor (reviewed in [106]). However, a recent review 
focused on human and animal trials testing lycopene, or lycopene-containing extracts, suggests that 
limited evidence exists for the "lycopene antioxidant hypothesis" as an in vivo mechanism of action. 
Some of the biological activity of the molecule can be attributed to its metabolic products   
(lycopenoids) [112]. 
Lycopene concentration in raw tomatoes ranges between 8.8–42 μg/g wet weight. These values 
increase to 86–100 μg/g and 63–131 μg/g for tomato juice and tomato sauce, respectively [28]. 
Therefore, the process of cooking usually makes lycopene more bioavailable due to its release from the 
matrix into the lipid phase of the meal [113]. Cis-isomers of lycopene are probably better absorbed 
than the all-trans form. This is due to the shorter length of the cis-isomer, the greater solubility of  
cis-isomers in mixed micelles, and the lower tendency of cis-isomers to aggregate [113]. All-trans 
lycopene accounts for 79% to 91% and cis isomers for 9% to 21% of total lycopene in tomatoes, 
tomato paste, and tomato soup. Lycopene concentrations in the serum of men range between 0.60 and  
1.9 nmol/mL, with 27% to 42% all-trans lycopene and 58% to 73% cis-isomers. In striking contrast 
with foods, all-trans lycopene accounts for only 12% to 21% and cis isomers for 79 to 88% of total 
lycopene in benign or malignant prostate tissues [114]. From these and other data derived that, in 
healthy human subjects treated with increasing doses of lycopene ranging from 10 to 120 mg, 
maximum total lycopene concentration was reached between 15.6 and 32.6 h with serum levels 
ranging between 0.075–0.210 M [115]. 
Lycopene bioavailability represents a key issue to explore the chemopreventive and 
chemotherapeutic properties of the molecule. The preferential in vivo bio-accumulation of lycopene 
isomers within prostate issue [116] suggested its potential involvement against prostate cancer. Several 
excellent reviews have been published on the antiproliferative and pro-apoptotic activity of lycopene 
on cell lines derived from human prostate cancer [106,117]. At non physiological concentration, 
lycopene triggers apoptosis activating the intrinsic pathway involving mitochondrial function, 
cytochrome C release and exposure to Annexin V. The antiproliferative activity of lycopene is mostly 
identified with the ability of the molecule to block the cell cycle at G0/G1 phase. This effect has been 
observed in prostate cancer, hepatocyte, and breast cancer cell lines [106]. It is worthwhile to note that 
contradictory results obtained by different groups on the same cell lines can be attributed to 
concentrations applied which, in some cases, differ of several orders of magnitude. In fact, a recent 
study which employed various different cancerous and noncancerous cell types, treated with lycopene 
from 0.0001 to 10 M for 24, 48, and 72 h, indicated that lycopene, at the physiological range, does 
not significantly affect cell proliferation, suggesting more careful investigations [118]. 
Since the publication of epidemiological data supporting the idea that consumption of lycopene rich 
diet lowers risk of prostate cancer [58,119], many studies supported the potential use of the molecule Toxins 2010, 2            
 
 
537
as chemopreventive agent based on data primarily coming from animal studies. However, also in this 
case, as for cell lines discussed above, a unanimous consensus has not been reached. As an example, in 
a xenograft model of BALB/c nude mice implanted with DU145 prostate cancer cells, administration 
of 100 and 300 mg/Kg of lycopene reduced tumor growth of 55.6% and 75.8%, respectively [120], 
while, in a different model represented by PC-346 C orthotopic mouse no effect was observed at a 
lower dose (5 or 50 mg/kg) [121]. Association with -tocopherol also slightly increased necrotic area 
in MatLyLu Dunning prostate tumor model [122]. A more recent study reports that lycopene inhibits 
experimental metastasis of human hepatoma SK-Hep-1 cells in athymic nude mice [123]. However, 
also this study has been partially questioned [124]. Despite these controversial data in animal model, 
the consistent number of epidemiological studies showing an inverse relationship between 
tomato/lycopene intake and risk of incurring in several types of cancer [125], stimulated an 
investigation from FDA for qualified health claims regarding tomatoes, lycopene and cancer risk. The 
FDA found no credible evidence to support an association between lycopene intake and a reduced risk 
of prostate, lung, colorectal, gastric, breast, ovarian, endometrial, or pancreatic cancer. The FDA also 
found no credible evidence for an association between tomato consumption and a reduced risk of lung, 
colorectal, breast, cervical, or endometrial cancer. The FDA found very limited evidence to support an 
association between tomato consumption and reduced risks of prostate, ovarian, gastric, and pancreatic 
cancers [126]. 
Actually, several phase I and II clinical trials essentially supported by research centers and 
University are ongoing worldwide (Table 2). Target patients are those with early stage prostate cancer, 
benign prostatic hyperplasia, before radical prostatectomy for prostate cancer, recurrent or metastatic 
prostate cancer. In several case (Table 2), combination supplements are tested to ameliorate patient 
conditions. Usually, these products are currently available on the market, as herb and vitamin 
supplements, not regulated by the FDA. Each single ingredient has been studied in prostate cancer 
cells and/or in patients with prostate cancer and at doses included in this supplement, no serious side 
effects have been reported. In the next future, results of these studies will hopefully clarify the 
potential pharmacological use of lycopene in cancer therapy. 
7. Resveratrol 
A number of excellent reviews have been recently published on resveratrol (3,4′,5-trihydroxy-trans-
stilbene), a phytoalexin firstly described as a component in the root of the weed Polygonum 
cuspidatum, whose extracts are very well known in Asian medicine [127–129] and also present in 
grape skin, wine and peanuts. Resveratrol raised his importance as a chemopreventive agent after a 
paper published in 1997 [130]. However, what seems paradoxical is the discovery that resveratrol was 
initially present in the scientific literature as cardiovascular protective agent, able to explain the 
“French paradox”. In fact, the molecule inhibits platelet aggregation, prevents LDL oxidation by 
means of its antioxidant properties, exerts vasorelaxing effect on animal model (reviewed in [131]). 
Finally, and more recently, resveratrol showed potential anti-ageing properties [132]. 
In vitro, resveratrol and its analogs trigger numerous intracellular pathways leading to cell growth 
arrest. As exhaustively reviewed in Table 1 of [128], several molecular targets have been identified in 
cell lines to support the anticancer activity of resveratrol, including deactivation of AhR   Toxins 2010, 2            
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(aryl hydrocarbon receptor) and CYP enzymes, activation of phase II detoxification and antioxidant 
enzymes, inhibition of pro-inflammatory mediators, regulation of cell cycle machinery, activation of 
pro-apoptotic factors and deactivation of anti-apoptotic compounds, inhibition of metastatic 
progression [1]. In several, but not all, cellular models, resveratrol causes block of cell cycle 
progression acting on modulating gene expression. In fact, the molecule is able to down-regulate 
cyclin D1, D2 and E expression and up-regulating the expression of the Cdk inhibitor p21
WAF1/CIP1 [133]. 
In parallel, the pleiotropic activity of resveratrol in inducing apoptosis is exerted by triggering both the 
extrinsic, death receptor-mediated, pathways and the intrinsic, mitochondrial pathways. In the first 
case, resveratrol induces apoptosis in colon cancer cell lines by redistribution of death receptors, CD95 
(Fas/Apo-1) and TRAIL (TNF-Related Apoptosis-Inducing Ligand), into lipid rafts. This effect 
sensitizes these tumor cells to death receptor-mediated apoptosis. Therefore, resveratrol does not 
enhance the number of death receptors at the surface of tumor cells but induces their redistribution into 
lipid rafts and facilitates the caspase cascade activation in response to death receptor stimulation [134]. 
Alternatively, resveratrol has recently been reported to suppress expression of anti-apoptotic proteins, 
such as survivin, Bcl-XL and Mcl-1 in NHL and MM cell lines [135]. Inhibition of Bcl-XL expression 
by resveratrol was mediated by inhibition of the ERK1/2 pathway (reviewed in [135]). 
Several in vivo studies, recently reviewed [127,129,136], sustain resveratrol efficacy in inhibiting or 
retarding tumor growth and/or progression in animal models inoculated with malignant cell lines, or 
treated with tumorigenesis-induced drugs (benzo-[a]pyrene, 7,12-dimethylbenz[a]anthracene, 
azoxymethane). However, lack of in vivo efficacy of resveratrol was reported by others [137]. The 
tumor preventive activity of resveratrol has been confirmed in a wide variety of experimental tumors 
including skin, liver, colon, breast, lung, and esophageal cancers. In general, the majority of these 
studies agree on the ability of the molecule to prevent chemically-induced malignancies and of 
reducing the efficiency of experimental protocols of tumorogenesis (reviewed in [136]). 
Sinclair’s group and others described the anti-ageing properties of resveratrol [138]. The molecule 
can extend the life span of yeast, worms, flies, and fish and mitigates the metabolic dysfunction of 
mice fed high-fat diets. Resveratrol appears to mediate these effects partly by activating sirtuin 
(SIRT1), a deacetylase enzyme that regulates the activity of several transcriptional factors and 
enzymes responsive to nutrient availability [132]. The pro-survival properties of resveratrol have been 
confirmed by a recent paper showing its ability to increase aerobic capacity in mice by inducing genes 
for oxidative phosphorylation and mitochondrial biogenesis in a SIRT1-dependent manner [139]. This 
appears as a potential contradiction respect to the chemopreventive activity of resveratrol: as an 
antioxidant, resveratrol counteracts ROS production and inhibit cell growth; however, as an anti-ageing 
compound, the same molecule increases mitochondrial metabolism and, in turns, ROS production, 
enhancing cell survival. In addition, while histone deacetylases “inhibitors” represent novel and potent 
chemotherapeutic drugs [140], resveratrol, apparently, functions in the same way “activating” the same 
enzymes. As discussed elsewhere [1], the in vivo bioavailability of the molecule may explain the 
controversial data on resveratrol mechanism of action. In fact, dietary resveratrol (up to 25 mg) is 
rapidly adsorbed and predominantly present in the plasma as glucoronide and sulfate conjugates. In 
addition, when administered in food, such as wine or grape juice, resveratrol metabolism is 
significantly inhibited by other polyphenols due to competitive reactions with metabolizing phase II 
enzymes, resulting in an increased concentration of the free form. Despite this, the free aglycone is Toxins 2010, 2            
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almost undetectable in human plasma [1,141]. Therefore, caution is suggested when interpreting the 
voluminous Literature on anticancer activity of resveratrol, only based on in vitro studies on cell lines 
where the molecule is given at pharmacological concentrations (25–50 M or higher), as aglycone, a 
form almost absent in plasma and urine [1]. The explanation for the functional pleiotropy of resveratrol 
might be found in the values of its circulating concentrations. In fact, the molecule activates in vivo 
SIRT1 at very low concentration (nanomolar range), a value potentially in agreement with resveratrol 
bioavailability. On the opposite, moving from physiological to pharmacological concentrations, as 
those employed in the in vitro experiments, predominates the anticancer properties of the molecule, 
such as inhibition of cell growth, activation of apoptotic events, arrest of cell cycle progression, 
depending on the cell line employed and the biomarkers analysed. 
Authors agree on the conclusion that despite the numerous reports describing the pharmacokinetics 
of resveratrol in animal model systems, there are only few similar studies in humans to date, and the 
large part of these data regards the administration of pure or dietary resveratrol (in wine and/or other 
beverages) in healthy subjects to assess its bioavailability in view of a chemopreventive use of the 
molecule, more than an its therapeutic use in cancer patients [127,136,142]. As an example, data from 
a case-control study, analyzed the relation between dietary intake of resveratrol and 50% or greater 
reductions in breast cancer risk in women with resveratrol consumption from grapes, but not from 
wine. The inverse relationship between resveratrol and breast cancer risk could not be explained by 
several potential confounding factors, including alcohol intake, nor was it attributable to a nonspecific 
favorable effect of fruit on breast cancer risk [142,143]. Similarly, a closed phase I clinical trial on 
healthy subjects is evaluating the effect of grape-derived low-dose resveratrol on biomarkers related to 
the Wnt pathway, a key signaling pathway activated in >85% of colon cancers. The same study is 
evaluating the utility of this approach for colon cancer prevention [142]. Ongoing clinical trials on 
phase I and II using resveratrol as pure compound or formulation with improved bioavailability   
(e.g., SRT501 from Sirtris Pharmaceuticals) are summarized in Table 2. In the first two trials, patient 
with colon cancer and resectable colorectal cancer, respectively, will receive oral doses of resveratrol 
to examine its effects directly on colon cancer and normal colonic mucosa and determine changes in 
several biomarkers, such as Wnt and COX-2 expression, Ki67 labeling index. The toxicity profile of 
the molecule will also be evaluated. In the two studies sponsored by Glaxo Smithkline (Table 2), the 
safety, pharmacokinetics and pharmacodynamics of SRT501 will be assessed in subjects diagnosed 
with colorectal cancer and hepatic metastases or MM. In the latter case, the efficacy of SRT501 will be 
evaluated in monotherapy or in combination with bortezomib. 
8. Conclusions 
Here we reviewed the anticancer activity of a group of phytochemicals representing good 
candidates for chemopreventive and chemotherapeutic applications. They have been selected among 
many others available in the literature to play the “truth or dare” game: do they really possess efficacy 
in cancer therapy? All compounds reviewed in the present work have in common the presence in the 
diet and a well documented anticancer activity in experimental models, namely cell cultures and 
animal models of induced carcinogenicity. These molecules are largely cited in the current literature 
and their activity is often associated with the term chemoprevention. However, we clearly showed here Toxins 2010, 2            
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that the translation from bench to clinics can be applied only to a limited number of them (Table 2). 
We underlined some critical issues generating controversy, such as the different order of magnitude of 
doses employed and the wide spectrum of biological processes affected by these compounds, ranging 
from cancer to ageing. To give a rationale explanation on how the same molecule can trigger pathways 
linked to different physio-pathological conditions, as in the case of resveratrol, is not an easy exercise. 
To increase confusion, in clinical trials referring to phytochemicals, it is not always clear when they 
are tested as potential chemopreventive or chemotherapeutic agents. The difference existing between 
primary and secondary chemoprevention and chemotherapy has been authoritatively defined [2,144,145]. 
Chemoprevention should be referred to “healthy” people who agree to receive a therapeutic treatment 
lasting, perhaps, years; therefore, safety represents a key issue in chemoprevention, since lack of 
toxicity or undesirable side effects are mandatory. In addition, practical considerations suggest only 
oral administration of the active principle as pills, capsules or similar formulations. On the opposite 
chemotherapy is applied to patient who already developed tumors and/or invasive cancers. In this case, 
drugs are given at pharmacological doses and their intrinsic toxicity is evaluated by a strict   
benefit-versus-risk analysis. Studies summarized in Table 2 essentially aim to evaluate how selected 
phytochemicals should be given (e.g., by mouth or injected into the blood), how often and what dosage 
is safe. When administered per os, phytochemicals can be found in free form in the blood only if they 
are taken at pharmacological doses (hundreds of milligrams). In fact, only in this case, they saturate 
the metabolic pathways of conjugation (methylation, sulfatation and glucuronidation) and are 
potentially bioavailable and biologically active [146]. Alternatively, they must be administered by 
intravenous injection to avoid that the formation of conjugates can reduce the bioavailability of the 
active moiety and dramatically alter their pharmacological properties. The correct dose will also 
determine the primary site of metabolism, with high doses primarily metabolized in the liver and low 
doses in the intestine. We listed above the attributes which a putative phytochemical compound should 
respect to be applied in chemoprevention. From this, it appears not easy to determine the adequate 
dose which is not neutralized by metabolizing enzymes, and, in parallel, is not too high to cause 
toxicity in humans. These obstacles are bypassed when the active compound is employed as 
chemotherapeutic agent against specific types of cancers. In this case, higher doses and a greater 
toxicity are acceptable, since the target is represented by patients with advanced cancers. Randomized 
phase III clinical trials employing phytochemicals as tested drugs are devoted to provide these data 
enrolling a large number of cancer patients. However, until now, only in few cases, e.g., curcumin 
(Table 2), trials with phytochemicals reached phase III. 
Finally, in the current attempts to translate the anticancer efficacy of phytochemicals into clinics, 
we cited several examples of combination therapy (Table 2), where anticancer compounds are given in 
association with well-known drugs currently used in chemotherapy. From a pharmacologic point of 
view, this strategy presents several advantages. Phytochemicals are functionally pleiotropic: we clearly 
showed that they possess multiple intracellular targets, affecting different cell signaling processes 
usually altered in cancer cells, with limited toxicity on normal cells. Targeting simultaneously multiple 
pathways may help to kill cancer cells and slow drug resistance onset. In addition, if proven, the 
association of pure or synthetic analogs of phytochemicals with chemotherapy or radiotherapy may 
take advantage of the synergic effects of the combined protocols, resulting in the possibility to lower 
doses and, consequently, reduce toxicity. Toxins 2010, 2            
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The results of the ongoing clinical trials may provide a foundation for designing future large-scale 
clinical trials to ascertain the full chemopreventive and chemotherapeutic efficacy of phytochemicals. 
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